Prostate specific antigen complexed to α-1-antichymotrypsin in patients with intermediate prostate specific antigen levels

Takashi Saika, Tomoyasu Tsushima, Yasutomo Nasu, Nobuyuki Kusaka, Yoshiyuki Miyaji, Hitoshi Takamoto, Katsuji Takeda, Satoru Uno, Hiromi Kumon

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

BACKGROUND. the authors attempted to evaluate prospectively the usefulness of serum prostate specific antigen (psa) complexed to α-1-antichymotrypsin (psa-act) in the early detection of prostate carcinoma and its ability to discriminate between prostate carcinoma and benign prostatic hyperplasia (bph), especially among patients with intermediate psa levels. METHODS. between december 1999 and august 2000, systematic sextant biopsies were performed on 281 prospective patients with prostate carcinoma who had serum psa levels between 4.1 ng/ml and 20.0 ng/ml. the serum samples were assayed by using kits that were designed specifically for measuring serum psa, psa-act, and free psa levels. the clinical values of psa, psa-act, the free psa to total psa ratio (f/t ratio), the free psa to psa-act ratio, psa density (psad), and psa-act density (actd) were compared by using receiver operating characteristic (roc) curve analysis. RESULTS. biopsy yielded no evidence of malignancy in 198 patients, and prostate carcinoma was confirmed in 83 patients. roc analysis demonstrated that the area under the curve (auc) for psa-act was greater than that for total psa and was equivalent to that for the f/t ratio in both groups of patients (psa ranges of 4.1-20.0 ng/ml and 4.1-10.0 ng/ml, respectively). the auc for the actd was greater than the auc for the psad and had the highest value of all parameters. CONCLUSIONS. the measurement of psa-act represents an alternative to the use of total and free psa. the actd value is the most useful for discriminating between bph and prostate carcinoma.

Original languageEnglish
Pages (from-to)1685-1691
Number of pages7
JournalCancer
Volume94
Issue number6
DOIs
Publication statusPublished - Mar 15 2002

Fingerprint

Prostate-Specific Antigen
Prostate
Carcinoma
Area Under Curve
Prostatic Hyperplasia
Serum
ROC Curve
Biopsy

Keywords

  • α-1-antichymotrypsin
  • Diagnosis
  • Free to total prostate specific antigen ratio
  • Prostate specific antigen
  • Prostate specific antigen density

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Prostate specific antigen complexed to α-1-antichymotrypsin in patients with intermediate prostate specific antigen levels. / Saika, Takashi; Tsushima, Tomoyasu; Nasu, Yasutomo; Kusaka, Nobuyuki; Miyaji, Yoshiyuki; Takamoto, Hitoshi; Takeda, Katsuji; Uno, Satoru; Kumon, Hiromi.

In: Cancer, Vol. 94, No. 6, 15.03.2002, p. 1685-1691.

Research output: Contribution to journalArticle

Saika, T, Tsushima, T, Nasu, Y, Kusaka, N, Miyaji, Y, Takamoto, H, Takeda, K, Uno, S & Kumon, H 2002, 'Prostate specific antigen complexed to α-1-antichymotrypsin in patients with intermediate prostate specific antigen levels', Cancer, vol. 94, no. 6, pp. 1685-1691. https://doi.org/10.1002/cncr.10377
Saika, Takashi ; Tsushima, Tomoyasu ; Nasu, Yasutomo ; Kusaka, Nobuyuki ; Miyaji, Yoshiyuki ; Takamoto, Hitoshi ; Takeda, Katsuji ; Uno, Satoru ; Kumon, Hiromi. / Prostate specific antigen complexed to α-1-antichymotrypsin in patients with intermediate prostate specific antigen levels. In: Cancer. 2002 ; Vol. 94, No. 6. pp. 1685-1691.
@article{80a69d045c1a415694bfb57c3f619744,
title = "Prostate specific antigen complexed to α-1-antichymotrypsin in patients with intermediate prostate specific antigen levels",
abstract = "BACKGROUND. the authors attempted to evaluate prospectively the usefulness of serum prostate specific antigen (psa) complexed to α-1-antichymotrypsin (psa-act) in the early detection of prostate carcinoma and its ability to discriminate between prostate carcinoma and benign prostatic hyperplasia (bph), especially among patients with intermediate psa levels. METHODS. between december 1999 and august 2000, systematic sextant biopsies were performed on 281 prospective patients with prostate carcinoma who had serum psa levels between 4.1 ng/ml and 20.0 ng/ml. the serum samples were assayed by using kits that were designed specifically for measuring serum psa, psa-act, and free psa levels. the clinical values of psa, psa-act, the free psa to total psa ratio (f/t ratio), the free psa to psa-act ratio, psa density (psad), and psa-act density (actd) were compared by using receiver operating characteristic (roc) curve analysis. RESULTS. biopsy yielded no evidence of malignancy in 198 patients, and prostate carcinoma was confirmed in 83 patients. roc analysis demonstrated that the area under the curve (auc) for psa-act was greater than that for total psa and was equivalent to that for the f/t ratio in both groups of patients (psa ranges of 4.1-20.0 ng/ml and 4.1-10.0 ng/ml, respectively). the auc for the actd was greater than the auc for the psad and had the highest value of all parameters. CONCLUSIONS. the measurement of psa-act represents an alternative to the use of total and free psa. the actd value is the most useful for discriminating between bph and prostate carcinoma.",
keywords = "α-1-antichymotrypsin, Diagnosis, Free to total prostate specific antigen ratio, Prostate specific antigen, Prostate specific antigen density",
author = "Takashi Saika and Tomoyasu Tsushima and Yasutomo Nasu and Nobuyuki Kusaka and Yoshiyuki Miyaji and Hitoshi Takamoto and Katsuji Takeda and Satoru Uno and Hiromi Kumon",
year = "2002",
month = "3",
day = "15",
doi = "10.1002/cncr.10377",
language = "English",
volume = "94",
pages = "1685--1691",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "6",

}

TY - JOUR

T1 - Prostate specific antigen complexed to α-1-antichymotrypsin in patients with intermediate prostate specific antigen levels

AU - Saika, Takashi

AU - Tsushima, Tomoyasu

AU - Nasu, Yasutomo

AU - Kusaka, Nobuyuki

AU - Miyaji, Yoshiyuki

AU - Takamoto, Hitoshi

AU - Takeda, Katsuji

AU - Uno, Satoru

AU - Kumon, Hiromi

PY - 2002/3/15

Y1 - 2002/3/15

N2 - BACKGROUND. the authors attempted to evaluate prospectively the usefulness of serum prostate specific antigen (psa) complexed to α-1-antichymotrypsin (psa-act) in the early detection of prostate carcinoma and its ability to discriminate between prostate carcinoma and benign prostatic hyperplasia (bph), especially among patients with intermediate psa levels. METHODS. between december 1999 and august 2000, systematic sextant biopsies were performed on 281 prospective patients with prostate carcinoma who had serum psa levels between 4.1 ng/ml and 20.0 ng/ml. the serum samples were assayed by using kits that were designed specifically for measuring serum psa, psa-act, and free psa levels. the clinical values of psa, psa-act, the free psa to total psa ratio (f/t ratio), the free psa to psa-act ratio, psa density (psad), and psa-act density (actd) were compared by using receiver operating characteristic (roc) curve analysis. RESULTS. biopsy yielded no evidence of malignancy in 198 patients, and prostate carcinoma was confirmed in 83 patients. roc analysis demonstrated that the area under the curve (auc) for psa-act was greater than that for total psa and was equivalent to that for the f/t ratio in both groups of patients (psa ranges of 4.1-20.0 ng/ml and 4.1-10.0 ng/ml, respectively). the auc for the actd was greater than the auc for the psad and had the highest value of all parameters. CONCLUSIONS. the measurement of psa-act represents an alternative to the use of total and free psa. the actd value is the most useful for discriminating between bph and prostate carcinoma.

AB - BACKGROUND. the authors attempted to evaluate prospectively the usefulness of serum prostate specific antigen (psa) complexed to α-1-antichymotrypsin (psa-act) in the early detection of prostate carcinoma and its ability to discriminate between prostate carcinoma and benign prostatic hyperplasia (bph), especially among patients with intermediate psa levels. METHODS. between december 1999 and august 2000, systematic sextant biopsies were performed on 281 prospective patients with prostate carcinoma who had serum psa levels between 4.1 ng/ml and 20.0 ng/ml. the serum samples were assayed by using kits that were designed specifically for measuring serum psa, psa-act, and free psa levels. the clinical values of psa, psa-act, the free psa to total psa ratio (f/t ratio), the free psa to psa-act ratio, psa density (psad), and psa-act density (actd) were compared by using receiver operating characteristic (roc) curve analysis. RESULTS. biopsy yielded no evidence of malignancy in 198 patients, and prostate carcinoma was confirmed in 83 patients. roc analysis demonstrated that the area under the curve (auc) for psa-act was greater than that for total psa and was equivalent to that for the f/t ratio in both groups of patients (psa ranges of 4.1-20.0 ng/ml and 4.1-10.0 ng/ml, respectively). the auc for the actd was greater than the auc for the psad and had the highest value of all parameters. CONCLUSIONS. the measurement of psa-act represents an alternative to the use of total and free psa. the actd value is the most useful for discriminating between bph and prostate carcinoma.

KW - α-1-antichymotrypsin

KW - Diagnosis

KW - Free to total prostate specific antigen ratio

KW - Prostate specific antigen

KW - Prostate specific antigen density

UR - http://www.scopus.com/inward/record.url?scp=0037086616&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037086616&partnerID=8YFLogxK

U2 - 10.1002/cncr.10377

DO - 10.1002/cncr.10377

M3 - Article

C2 - 11920529

AN - SCOPUS:0037086616

VL - 94

SP - 1685

EP - 1691

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 6

ER -